Mutated Salmonella enteriaca

Patent metadata

Field	Value
Publication number	US-9868769-B2
Application number	US-201415108725-A
Country	US
Kind code	B2
Filing date	Dec 29, 2014
Priority date	Jan 6, 2014
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.

First claim

We the inventors claim:

1. A mutated S. enterica serovar Typhimurium comprising a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes.

2. The mutated S. enterica serovar Typhimurium of claim 1 , wherein said S. enterica serovar Typhimurium is strain BBS 866 deposited under the accession NRRL B-50989 or strain BBS 1134 deposited under the accession NRRL B-50990.

3. An immunogenic composition comprising a pharmaceutically acceptable carrier or diluent and a mutated S. enterica serovar Typhimurium comprising a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes.

4. The immunogenic composition of claim 3 , further comprising an adjuvant.

5. The immunogenic composition of claim 3 , wherein said mutated S. enterica serovar Typhimurium is attenuated or inactivated.

6. The immunogenic composition of claim 5 , wherein said inactivated S. enterica serovar Typhimurium is a bacterial ghost.

7. A method of inducing an immune response in an animal to S. enterica comprising administering to said animal an immunologically effective amount of the immunogenic composition of claim 3 .

8. The method of claim 7 , wherein said immunogenic composition further comprises an adjuvant.

9. The method of claim 7 , wherein said novel, mutated S. enterica serovar Typhimurium in said immunogenic composition is attenuated or inactivated.

10. A method of reducing an animal's carriage of S. enterica comprising administering to said animal an immunologically effective amount of the immunogenic composition of claim 3 , wherein said immunologically effective amount of said immunogenic composition generates an immune response in said animal that reduces said S. enterica carriage.

11. The method of claim 10 , wherein said immunogenic composition further comprises an adjuvant.

12. The method of claim 10 , wherein said mutated S. enterica serovar Typhimurium in said immunogenic composition is attenuated or inactivated.

13. A method of reducing S. enterica colonization of an animal comprising administering to said animal an immunologically effective amount of the immunogenic composition of claim 3 , wherein said immunologically effect amount of said immunogenic composition generates an immune response in said animal which reduces said S. enterica colonization.

14. The method of claim 13 , wherein said immunogenic composition further comprises an adjuvant.

15. The method of claim 13 , wherein said mutated S. enterica serovar Typhimurium in said immunogenic composition is attenuated or inactivated.

16. A kit comprising a first container comprising a mutated S. enterica serovar Typhimurium; a second container comprising a pharmaceutically acceptable carrier or diluent; written instructions for use; and optionally a third container comprising an adjuvant, wherein said mutated S. enterica serovar Typhimurium comprises a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes.

17. The kit of claim 16 , wherein said mutated S. enterica serovar Typhimurium is attenuated or inactivated.

18. The kit of claim 16 , wherein said mutated S. enterica serovar Typhimurium is selected from the group consisting of S. enterica serovar Typhimurium strain BBS 866 deposited under the accession NRRL B-50989 , S. enterica serovar Typhimurium strain BBS 1134 deposited under the accession NRRL B-50990, and a combination thereof.

19. The immunogenic composition of claim 3 , wherein said mutated S. enterica serovar Typhimurium selected from the group consisting of S. enterica serovar Typhimurium strain BBS 866 deposited under the accession NRRL B-50989 , S. enterica serovar Typhimurium strain BBS 1134 deposited under the accession NRRL B-50990, and a combination thereof.

20. An immunogenic composition comprising a pharmaceutically acceptable carrier or diluent and a membrane fraction of a mutated S. enterica serovar Typhimurium comprising a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes.

21. The method of claim 7 , wherein the immune response that is induced is cross-reactive with S. enterica serovar Typhimurium , S. enterica serovar Choleraesuis, and S. enterica serovar Heidelberg.

22. The method of claim 10 , wherein said S. enterica carriage is due to S. enterica serovar Typhimurium , S. enterica serovar Choleraesuis, or S. enterica serovar Heidelberg.

23. The method of claim 13 , wherein the generated immune response is cross-reactive with S. enterica serovar Typhimurium , S. enterica serovar Choleraesuis, and S. enterica serovar Heidelberg.

Assignees

• Us Agriculture

Inventors

• Bearson Bradley L
• Bearson Shawn M

Classifications

• A61K2039/522

  avirulent or attenuated · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• A61K2039/543

  intranasal · CPC title

• A61K2039/58

  raising an immune response against a target which is not the antigen used for immunisation · CPC title

• A61K39/0275

  Salmonella · CPC title